Risk of SARS-CoV-2 infection during the omicron surge in patients on dialysis

antibody

In a recent study published in Journal of the American Society of Nephrology, a third COVID-19 mRNA vaccine dose in adults with kidney failure who were on dialysis enhanced patients’ protection against SARS-CoV-2 infection during the omicron-dominant period. A patient’s response to vaccination or prior infection—as measured by circulating anti-SARS-CoV-2 antibody levels—was also an important predictor for subsequent risk of infection.

In the study of randomly-selected patients receiving dialysis in the United States, a team led by Shuchi Anand, MD, MS, Pablo Garcia, MD, MS, and Maria Montez Rath, Ph.D. (Stanford University School of Medicine) followed patients’ monthly anti–SARS-CoV-2 antibody levels and ascertained COVID-19 infection during the omicron- dominant period of December 25, 2021 to January 31, 2022 using electronic health records.

Among 3,576 patients receiving dialysis, 901 (25%) received a third mRNA vaccine dose as of December 1, 2022, and early antibody responses to third doses were robust. During the omicron-dominant period, SARS-CoV-2 infection was documented in 340 (7%) patients. Risk for infection was doubled among patients without vaccination and nearly 1.5-fold higher with 1–2 doses compared with 3 doses. Irrespective of vaccine doses, risk for infection was at least 2-fold higher among patients with low circulating levels of anti–SARS-CoV-2 antibodies.

Source: Read Full Article

Related posts:
  1. New rules for lung transplants lead to unintended consequences
  2. Officials are still searching for arrivals from Wuhan in the UK
  3. Great Ormond Street Hospital for Children NHS FT awarded Stage 7 O-EMRAM
  4. Older adults can be more focused, less mentally restless than younger adults
  5. Early Diagnosis of Bronchiectasis Critical in T2 Severe Asthma